

He Du

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8841192/publications.pdf>

Version: 2024-02-01

9
papers

109
citations

1937685

4
h-index

1588992

8
g-index

10
all docs

10
docs citations

10
times ranked

115
citing authors

#	ARTICLE	IF	CITATIONS
1	Elevated TRIM23 expression predicts cisplatin resistance in lung adenocarcinoma. <i>Cancer Science</i> , 2020, 111, 637-646.	3.9	38
2	Elevated Glutathione Peroxidase 2 Expression Promotes Cisplatin Resistance in Lung Adenocarcinoma. <i>Oxidative Medicine and Cellular Longevity</i> , 2020, 2020, 1-14.	4.0	32
3	<scp>CEACAM6</scp> promotes cisplatin resistance in lung adenocarcinoma and is regulated by <scp>microRNA</scp>â€146a and <scp>microRNA</scp>â€26a. <i>Thoracic Cancer</i> , 2020, 11, 2473-2482.	1.9	11
4	MicroRNA-663 prevents monocrotaline-induced pulmonary arterial hypertension by targeting TGF-Î²1/smad2/3 signaling. <i>Journal of Molecular and Cellular Cardiology</i> , 2021, 161, 9-22.	1.9	11
5	Prognostic Nomogram Based on Circular RNA-Associated Competing Endogenous RNA Network for Patients with Lung Adenocarcinoma. <i>Oxidative Medicine and Cellular Longevity</i> , 2021, 2021, 1-13.	4.0	6
6	The safety and efficacy of immunotherapy with anti-programmed cell death 1 monoclonal antibody for lung cancer complicated with Mycobacterium tuberculosis infection. <i>Translational Lung Cancer Research</i> , 2021, 10, 3929-3942.	2.8	6
7	Analysis of risk factors for thrombosis of the left atrium/left atrial appendage in patients with non-valvular atrialfibrillation. <i>Cardiovascular Journal of Africa</i> , 2021, 32, 6-12.	0.4	2
8	Efficacy of ICIs on patients with oncogene-driven non-small cell lung cancer: a retrospective study. <i>Cancer Drug Resistance (Alhambra, Calif)</i> , 2022, 5, 15-24.	2.1	2
9	Distinct Prognostic Values of the mRNA Expression of Glucose Transporters in Non-Small Cell Lung Cancer. <i>Annals of Clinical and Laboratory Science</i> , 2020, 50, 481-489.	0.2	1